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Abstract
OBJECTIVE: To investigate the clinical efficacy and
safety of Tongguanteng (Radix seu Herba Marsdeni-
ae Tenacissimae) extract combined with chemother-
apy in the treatment of advanced non-small cell
lung cancer (NCSLC) compared with chemotherapy
alone.
METHODS: Databases including Chinese National
Knowledge Infrastructure, China Biology Medicine
Disc, Wanfang, and MEDLINE were searched until
April 1, 2014. Two assessors independently re-
viewed each trial. The primary outcome was the ef-
fective rate (ER) of Tongguanteng (Radix seu Herba
Marsdeniae Tenacissimae) extract combined with
chemotherapy. The secondary outcomes included
quality of life improvement rate (QOLIR) and ad-
verse reactions. Statistical calculations were per-
formed by using Cochrane Collaboration Review
Manager 5.2.
RESULTS: A total of 888 patients from 15 studies,
13 randomized controlled trials (RCT) and two con-
trolled clinical trials, were included. Compared with
chemotherapy alone, Tongguanteng (Radix seu Her-
ba Marsdeniae Tenacissimae) extract plus chemo-
therapy significantly improved ER [Risk ratio (RR) =
1.32, 95% CI, (1.14, 1.54)] (based on 15 studies) and
QOLIR [RR = 2.04, 95% CI, (1.69, 2.47)] (based on 13
studies). Compared with chemotherapy alone,
Tongguanteng (Radix seu Herba Marsdeniae Tenacis-
simae) extract plus chemotherapy significantly in-
hibited chemotherapy-induced white blood cell de-
cline [RR = 0.79, 95% CI, (0.70, 0.90) (based on 10
studies), chemotherapy-induced platelet decline
[RR = 0.77, 95% CI, (0.60, 0.98)] (based on 8 studies),
and significantly alleviated nausea and vomiting
(NV) [RR = 0.83, 95% CI, (0.71, 0.97)] (based on 7
studies). There was no significant difference in he-
moglobin decline between the two therapies [RR =
0.88, 95% CI, (0.70, 1.09)] (based on 6 studies).
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CONCLUSION: This Meta-analysis suggests that
Tongguanteng (Radix seu Herba Marsdeniae Tenacis-
simae) extract combined with chemotherapy may
be more efficacious in the treatment of advanced
NSCLC than chemotherapy alone. This effect in-
cludes enhancing ER and QOLIR, and weakening
chemotherapy toxicity. However, large-scale RCTs
are required to further investigate the short- and
long-term effects of Tongguanteng (Radix seu Her-
baMarsdeniae Tenacissimae) extract.
© 2016 JTCM. All rights reserved.
Key words: Carcinoma, non-small-cell lung; Mars-
denia tenacissima; Xiaoaiping injection; C21 steroi-
dal saponins; Drug therapy; Review; Meta-analysis
INTRODUCTION
Lung cancer is the leading cause of cancer-related
death in males in 2008 worldwide and second among
females1 Non-small cell lung cancer (NSCLC) ac-
counts for approximately 85% of all cases lung cancer.2
Patients with advanced NSCLC usually lose best opera-
tion time because approximately one third are diag-
nosed with other locally advanced disease. Moreover,
5-year survival rates in patients with advanced NSCLC
are less than five percent.3
Radiotherapy and chemotherapy are the main treat-
ments of advanced NSCLC. Despite these therapies,
there are no treatment protocols that can reliably
achieve complete remission. In addition, adverse reac-
tions from treatment present another challenge. There-
fore, adjuvant therapies are needed to improve quality
of life (QOL), prolong survival time, and reduce ad-
verse reactions. Some Traditional Chinese Medicines
(TCM) might have effects on treatments including in-
creasing sensitivity of the radiotherapy and chemothera-
py reducing clinical symptoms, increasing survival rate,
improving QOL, and decreasing adverse reactions in
patients with advanced NSCLC.4,5
Tongguanteng, or Marsdenia tenacissima (Roxb.)
Moon, is a traditional Chinese herbal medicine that is
mainly found in the Guizhou and Yunnan provinces of
China. Water extract of Tongguanteng (Radix seu Her-
ba Marsdeniae Tenacissimae) with trade name Xiaoaip-
ing (XAP) injection has been used for advanced
NSCLC in China over the last decade.
XAP injection is produced by SanHome Pharmaceuti-
cal Co., Ltd. (Nanjing, China) and was approved by
the China Food and Drug Administration (CFDA) for
tumor treatment with approval number Z20025868.
XAP injection is frequently used in China combined
with radiotherapy and chemotherapy in the treatment
of certain tumors.6-10 Water extract of Tongguanteng
(Radix seu Herba Marsdeniae Tenacissimae) contains ste-
roidal saponins, phenolic acids, alkaloids, polysaccha-
rides, and other compounds.11,12 Several C21 steroidal
glycosides have been isolated from the stem of Tong-
guanteng (Radix seu Herba Marsdeniae Tenacissimae).13
C21 steroidal saponins exhibited significant tumor
growth inhibition activity in K562 cell-bearing nude
mice,14 suggesting that C21 steroidal saponins are re-
sponsible for the anti-tumor activities of Tongguanteng
(Radix seu Herba Marsdeniae Tenacissimae).15
We aimed to use Meta-analysis to investigate the
short-term clinical efficacy and safety of Tongguanteng
(Radix seu Herba Marsdeniae Tenacissimae) extract
(XAP injection) combined with chemotherapy com-
pared with chemotherapy treatment alone in patients
with advanced NSCLC.
MATERIALS ANDMETHODS
Literature search
We searched the following databases: Chinese National
Knowledge Infrastructure (CNKI) (1979-1-2014-4),
China Biology Medicine Disc (CBMdisc) (1978-1-
2014-4), Wanfang Data (1998-1-2014-4), and MED-
LINE (1966-1-2014-4) from the date of their incep-
tion to 1 April 2014. Search terms included "Xiaoaip-
ing," "Xiaoaiping zhusheye," "Xiaoaiping injection,"
"Tongguanteng," "Marsdenia tenacissima," "Wuguteng,
" "C21 steroids," "Lung cancer," "Non-small cell lung
cancer," and "NSCLC." The search strategy was pre-
sented as follows:
#1 Xiaoaiping;
#2 Xiaoaipin;
zhusheye;
#3 Xiaoaiping injection;
#4 Tongguanteng;
#5 Marsdenia tenacissima;
#6 Wuguteng;
#7 C21 steroids;
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7;
#9 Non-small cell lung cancer;
#10 Lung cancer;
#11 NSCLC;
#12 #9 OR #10 OR #11;
#13 #8 AND #12
Study design
All randomized controlled trials (RCTs) and controlled
clinical trials (CCTs) on clinical efficacy and safety of
XAP injection combined with chemotherapy com-
pared with chemotherapy treatment alone in patients
with advanced NSCLC were searched without limita-
tion of language or publication type.
Inclusion criteria
Included studies met the following criteria: (a) All sub-
jects of the study were diagnosed with advanced
NSCLC. (b) Kanofsky Performance Status (KPS) score
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of patients was greater than or equal to 50, or Eastern
Cooperative Oncology Group (ECOG) score of pa-
tients was less than 3.16 (c) All subjects in the study un-
derwent one or two treatment cycles (about 21-30 days
in total). (d) There were no contraindications before
initiation of chemotherapy. (e) Evaluation of the clini-
cal efficacy of XAP injection combined with chemo-
therapy was performed in accordance with internation-
ally recognized standards. (f ) XAP injection (Nanjing
Sanhome Pharmaceutical Co., Ltd.,) was given intrave-
nously.
Evaluation index and internationally recognized
standards
Response Evaluation Criteria in Solid Tumors (RE-
CIST) were used for short-term clinical efficacy evalua-
tion.17 The effective rate (ER) was calculated with the
formula: [Number of cases with complete remission
[(CR) + partial remission (PR)]/(Total number of cas-
es) × 100%. QOL was evaluated with KPS score. The
quality of life improvement rate (QOLIR) was calculat-
ed with the formula: [(Number of cases with improve-
ment) / Total number of cases] × 100%. Adverse reac-
tions included nausea, vomiting (NV) and decreases in
white blood cell count (WBC), hemoglobin (Hb), or
platelets (Plt), which were monitored and categorized
into different degrees of severity, 0-IV, according to
WorldHealthOrganization (WHO) evaluation criteria.18
Study selection and data collection
All articles were reviewed independently by two asses-
sors (Zhang and Zhang, and disagreements were set-
tled through discussion or consultation with corre-
sponding author (Chen). Data were extracted from the
articles according to a standardized data extraction
form, including patients, methods, interventions, and
outcomes.
Statistical analysis
Statistical calculations were performed using Cochrane
Collaboration Review Manager (RevMan) 5.2. 19 Data
are expressed as risk ratio (RR) with 95% confidence
interval (CI). Heterogeneity was analyzed based on I 2
value. Studies with an I 2 statistic of < 25% were con-
sidered homogeneous, those with an I 2 of 25%-50%
were considered to have low heterogeneity, those with
an I 2 of 50%-75% were considered to have moderate
heterogeneity, and those with an I 2 of > 75% were con-
sidered to have high heterogeneity.19 If heterogeneity ex-
isted in pooled studies (I 2 < 50%, P > 0.1), a fix model
was used; otherwise the random model was used (I 2 >
50%, P < 0.1).20 Funnel plot was used to evaluate po-
tential publication bias if at least ten trials were avail-
able for a Meta-analysis. Statistical significance was con-
sidered P < 0.05.
RESULTS
Study selection
There were 33 studies initially identified by the data-
base search, including 2 studies in English and 31 in
Chinese. The 33 articles were reviewed by title and ab-
stract, and 20 met initial screening criteria. After care-
fully reading the full text of the 20 papers, 5 were ex-
cluded and 15 studies were included according to the
eligibility criteria. The study flow chart is shown in Fig-
ure 1. The 15 studies included 13 RCTs21-33 and 2
CCTs.34,35 A total of 888 patients were enrolled (443 in
treatment group and 445 in control group).
Characteristics of included subjects and studies
Characteristics of included subjects and studies are
shown in Tables 1 and 2. All studies were carried out in
People's Republic of China and all patients were Chi-
nese. Eleven studies included staging of the NSCLC tu-
mor-node-Metastasis (TNM)21-27,29,31,34,35 and expected
lifetime.21-29,34,35 KPS score was used in 14 studies21-28,30-35
and ECOG score was used in only one study.29 Twelve
Figure 1 Flow diagram showing the trial selection process for the Meta-analysis
Records initially identified through data-
base searching (n = 33)
Records remaining after title and abstract
screening (n = 20)
Records include in meta-analysis (n = 15)
Excluded after title/abstract screening
(n = 13)
1. Reviews (n = 4)
2. In vitro (n = 2)
3. Not meet the topical (n = 7)
Excluded after articles screening (n = 5)
1. Duplicate publication (n = 2)
2. Intramuscular injection (n = 1)
3. Lack of recognized standards (n = 1)
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Study
Song CP 200821
Huang ZQ 200734
Li J 200935
Luan TW 201322
Wang K 200923
Wang WY 200924
Xia GA 201325
Yang H 201126
Zhang FY 201127
Zhang RX 201228
Wang SB 201329
Wang YT 201230
Liu Z 200831
Zhang ZH 201232
Zhang XH 200933
Patient
number
36
30
38
35
28
27
39
30
24
35
25
28
34
16
18
Study
design
RCT
CCT
CCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
Level of
evidence
1
3
3
1
1
1
1
1
1
1
1
1
1
1
1
Exclusion
criteria
H
H
H
H
H
H
H
H
H
H
H
﹣
H
H
H
Clinical efficacy
ER
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Quality of life
QOLIR
H
H
H
H
H
H
﹣
H
H
H
H
H
H
﹣
﹣
Adverse reaction
WBC
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
Hb
H
H
H
﹣
H
﹣
﹣
﹣
H
H
﹣
H
﹣
﹣
﹣
Plt
H
H
H
H
H
﹣
﹣
﹣
H
H
H
H
﹣
﹣
﹣
NV
H
H
H
H
﹣
﹣
﹣
H
﹣
H
H
H
H
H
﹣
Table 1 Characteristics of included studies
Notes: RCT: randomized controlled trials; CCT: controlled clinical trials; ER: effective rate; QOLIR: quality of life improvement rate;
WBC: white blood cells; Hb: hemoglobin; Plt: platelet; NV: nausea and vomiting; H: detailed data in the literature; -: no data in the litera-
ture.
Study
Song CP 200821
Huang ZQ 200734
Li J 200935
Luan TW 201322
Wang K 200923
Wang WY 200924
Xia GA 201325
Yang H 201126
Zhang FY 201127
Zhang RX 201228
Wang SB 201329
Wang YT 201230
Liu Z 200831
Zhang ZH 201232
Zhang XH 200933
Performance
status
KPS≥60
KPS≧50
KPS≧70
KPS≧60
KPS≧50
KPS≧70
KPS≧50
KPS≧60
KPS≧50
KPS≧ 60
ECOG<3
KPS≧60
KPS≧50
KPS≧70
KPS≧60
Disease
staging
Ⅲa-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
Ⅲb-Ⅳ
﹣
Ⅲb-Ⅳ
﹣
Ⅲb-Ⅳ
﹣
﹣
Expected
lifetime
(months)
≧3m
>3m
>3m
>3m
>3m
>3m
≧3m
>3m
>3m
≧3m
>3m
﹣
﹣
﹣
﹣
Treatment group
XAP 60 mL+NP
XAP 60 mL+NP/
GP/CT
XAP 40 mL+GP
XAP 60 mL+NP/
GP/TP/PC
XAP 40-60 mL+
NP
XAP 80 mL+TP
XAP 40 mL+TP
XAP 60 mL+NP
XAP 40-60 mL+
GP
XAP 60 mL+GP
XAP 80 mL+CT
XAP 40-60 mL+
GP
XAP 20 mL+NP
XAP 40-60 mL+
PC
XAP 40 mL+NP
Control group
NP
NP/GP/CT
GP
NP/GP/TP/PC
NP
TP
TP
NP
GP
GP
CT
GP
NP
PC
NP
Treatment
cycle
2
2
2
2
2
2
2
2
2
2
2
2
2
1
2
Contraindications
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Notes: KPS: kanofsky performance status score; ECOG: eastern cooperative oncology group score; XAP: Xiaoaiping injection; NP: navel-
bine + cis-dichlorodiamineplatinum (DDP); TP: paclitaxel + DDP; GP: gemcitabine + DDP; CT: paclitaxel + carboplatin; H: detailed da-
ta in the literature; -: no data in the literature; N: patients have no contraindications to chemotherapy.
Table 2 Characteristics of included advanced non-small cell lung cancer subjects
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studies reported QOLIR results.21-24,26-31,34,35 Adverse reac-
tions were described in all included studies. Adverse
events two degrees above (Ⅱ-Ⅳ) were reported in 3
studies,21,31,32 and three degrees above were reported
(Ⅲ-Ⅳ) in 2 studies.24,25 Ten studies reported above one
degree adverse events (Ⅰ-Ⅳ).22,23,26-30,33-35 Four studies re-
ported immune function testing but the results were
not standard.23,24,27,34 Decreases in Hb, Plt, and symp-
toms of NV were not reported in 8 studies,22,24-26,29,31-33 6
studies,24-26,31-33 and 5 studies,23-25,27,33 respectively.
Study quality
Although the 13 RCTs claimed to be randomized con-
trolled trials, only 2 provided specific information on
randomization methods.24,32 We assessed the quality of
literature and methodology by contacting the study au-
thors. All randomized controlled trails were defined as
level 1 and controlled clinical trials included as level 3,
on the basis of study design.36 No studies mentioned
blinding procedure or allocation concealment.
Effective rate
As shown in Figure 2, 15 studies including 888 pa-
tients were suited to our Meta-analysis. There were 443
patients with advanced NSCLC in the XAP injection
combined with chemotherapy group and 445 in the
chemotherapy group. Our analysis showed that I 2 =
0% (I 2 < 25%) and P = 0.98 (P > 0.1), indicating the
studies were not heterogeneous. The fixed effects mod-
el was applied. Meta-analysis showed that there was a
significant difference between the XAP injection com-
bined with chemotherapy group and the chemotherapy
group [RR = 1.32, 95% CI (1.14, 1.54), P = 0.0003],
and the effect rate of XAP injection combined with
chemotherapy was much better than that of chemo-
therapy alone.
Quality of life improvement rate
As shown in Figure 3, 13 studies reported data on
QOLIR, including 370 patients in the XAP injection
combined with chemotherapy treatment group and
Figure 2 Forest plot of effective rate
XAP: Xiaoaiping injection.
Figure 3 Forest plot of the effects on QOLIR
XAP: Xiaoaiping injection; QOLIR: quality of life improvement rate.
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374 in the chemotherapy group. Meta-analysis data re-
vealed that I 2 = 27% (25% < I 2 < 50%) and P = 0.18
(P > 0.1), indicating the studies had a low level of het-
erogeneity. The fixed effects model was applied. Me-
ta-analysis showed that, compared with chemotherapy
alone, XAP injection combined with chemotherapy sig-
nificantly improved the QOLIR of patients [RR =
2.04, 95% CI (1.69, 2.47), P < 0.000 01].
Bone marrow inhibition
Among the trials included in our Meta-analysis, 10
studies including 582 patients reported results of WBC
analysis. As shown in Figure 4, Meta-analysis data dem-
onstrated that I 2 = 19% (I 2 < 25%) and P = 0.27 (P >
0.1), indicating the studies were not heterogeneous.
The fixed effects model was applied. Meta-analysis re-
vealed that the WBC levels of patients in the XAP in-
jection combined with chemotherapy group were sig-
nificantly higher than those in the chemotherapy
group [RR = 0.79, 95% CI (0.70, 0.90), P = 0.0003].
Hemoglobin levels
A total of 366 participants from 6 studies were includ-
ed in the analysis on the changes of Hb. The studies
were not heterogeneous with I 2 = 0% (I 2 < 25%) and
P = 0.88 (P > 0.1), so the fixed effects model was em-
ployed. Although XAP injection combined with che-
motherapy could prevent Hb decline, there was no sig-
nificant difference between the groups [RR = 0.88,
95% CI (0.70, 1.09), P = 0.24], as shown in Figure 5.
Platelet levels
There were 8 studies including 388 patients that re-
ported the results of Plt analysis. Our data (Figure 6)
show that I 2 = 0% (I 2 < 25%) and P = 0.84 (P >
0.1), indicating no heterogeneity. The fixed effects
model was used. Meta-analysis revealed that Plt levels
in the XAP injection combined with chemotherapy
group were significantly higher than those in the che-
motherapy group [RR = 0.77, 95% CI (0.60, 0.98),
P = 0.04].
Nausea and vomiting
As shown in Figure 7, 7 studies including 444 patients
reported NV adverse reactions. The studies had low
heterogeneity with I 2 = 31% (25% < I 2 < 50%) and
P = 0.19 (P > 0.1). The fixed effects model was ap-
plied. There was significantly less chemotherapy-in-
duced NV reported in the XAP injection combined
with chemotherapy group than in the chemotherapy
group [RR = 0.83, 95% CI (0.71, 0.97), P = 0.02].
Publication bias
The funnel plot appeared almost symmetrical, indicat-
ing that there was no potential publication bias among
the included studies (Figure 8).
Figure 4 Forest plot of effects on inhibition ofWBC decline
XAP: Xiaoaiping injection;WBC: white blood cells.
Figure 5 Forest plot of the effects on inhibition of Hb decline
XAP: Xiaoaiping injection; Hb: hemoglobin.
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DISCUSSION
Although certain chemotherapies have been effective
for the treatment of advanced NSCLC, adverse reac-
tions are substantial and inevitable. Therefore, adju-
vant therapies are urgently needed to improve QOL,
prolong survival time, and reduce adverse reactions.
Chinese herbal medicines (CHM) extracts, such as
Kanglaite injection, Aidi injection, and Shenmai injec-
tion as adjuvant therapies are frequently combined
with chemotherapy in China for the treatment of ad-
vanced NSCLC.37-39
According to the theories of TCM, Tongguanteng (Ra-
dix seu Herba Marsdeniae Tenacissimae), also called
Tongguanteng or Wuguteng in China, tastes bitter
with a slightly sweet and cool nature, and has Qingre
Jiedu effects (clearing heat and detoxifying), Huatan
Ruanjian (eliminating sputum and softening hard
mass), Xiaoyan Zhitong (eliminating inflammation
and pain), and Zhike Pingchuan (relieving cough and
asthma). Modern studies have shown that C21 steroi-
dal saponins are the main components of Tongguan-
teng (Radix seu Herba Marsdeniae Tenacissimae), and
have anti-tumor effects. For example, Zhang et al 40
found that steroidal aglycones from Tongguanteng (Ra-
dix seu Herba Marsdeniae Tenacissimae) inhibited the
Hedgehog signaling pathway in vitro, which is activat-
ed in advanced NSCLC and correlates with prognostic
factors of the tumors.41 Tongguanteng (Radix seu Herba
Marsdeniae Tenacissimae) extract significantly inhibited
the proliferation of ASTC-a-1 cells and induced cell
death by activating pro-caspase-3 molecules and pro-
teins.42 Tongguanteng (Radix seu Herba Marsdeniae Te-
nacissimae) ethanolic extract exerted anti-tumor effects
by inducing apoptosis and inhibiting proliferation of
human hematologic neoplasm cells in vitro and in vi-
vo.43 Tenacissoside C, a C21 steroidal saponin deriva-
tive, exhibited significant tumor growth inhibition in
K562 cell-bearing nude mice.14 Furthermore, Tong-
guanteng (Radix seu Herba Marsdeniae Tenacissimae) ex-
tract combined with gefitinib could overcome the gefi-
tinib resistance in NSCLC cells,44 and enhance gefi-
tinib efficacy by improving its Metabolic stability.45
Tongguanteng (Radix seu Herba Marsdeniae Tenacissi-
Figure 6 Forest plot of the effects on inhibition of Plt decline
XAP: Xiaoaiping injection; Plt: platelet.
Figure 8 Funnel plot of all studies included
RR: Risk ratio.
0
0.2
0.4
0.6
0.8
1.00.05 0.2 1 5 20
SE (log［RR］)
RR
Figure 7 Forest plot showing the effects of XAP injection combined with chemotherapy compared to single chemotherapy on al-
leviation of NV
XAP: Xiaoaiping injection; NV: nausea and vomiting.
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mae) extract could enhance the effects of doxorubicin
chemotherapy, an effect that might be related to the
up-regulation of Fas expression in tumor cells.46 Tenaci-
genin B might modulate P-glycoprotein-mediated mul-
tidrug resistance by directly interacting with the P-gly-
coprotein substrate site.47 In addition, Tongguanteng
(Radix seu Herba Marsdeniae Tenacissimae) extract in-
hibited the proliferation of HUVECs by preventing
cell cycle progression from G1 to S,48 and enhanced the
cellular and humoral immune systems.49 Substantial
clinical trials and animal experiments have shown that
Tongguanteng (Radix seu Herba Marsdeniae Tenacissi-
mae) extract exerts anti-tumor effects, but studies on
the anti-tumor mechanisms are still in their beginning
stages. Therefore, further studies should aim to study
the basic anti-tumor effects of Tongguanteng (Radix
seu Herba Marsdeniae Tenacissimae) extract. Future
studies on CHM should present the Latin scientific
names and adhere to the recommended reporting
guidelines of the CHM.50,51
Although XAP injection combined with chemotherapy
has been used for the treatment of advanced NSCLC,
the effect of XAP injection combined with chemothera-
py remains controversial. Some studies reported posi-
tive results,21,22,28 while others found no significant
changes compared to chemotherapy alone.24,30,32 Results
of our present Meta-analysis suggest that combining
chemotherapy with XAP injection, an anti-tumor
agent extracted from Tongguanteng (Radix seu Herba
Marsdeniae Tenacissimae), in the treatment of advanced
NSCLC enhances the ER and QOLIR, and weakens
the toxicities of chemotherapy, compared with treat-
ment of chemotherapy alone.
Despite these important findings, our study has some
limitations. First, our analysis was based on 13 RCTs
and 2 CCTs, all of which had a relatively small sample
size. This Meta-analysis found that the methodological
quality of included studies was poor. Overestimation of
the treatment effect is more likely in smaller trials com-
pared with larger trials. Second, the blinding proce-
dures were not applied in all studies, potentially result-
ing in performance bias and measurement bias. More-
over, because subjective indicators were used to evalu-
ate the curative effect and allocation was not used in
concealment in all studies, there could have been selec-
tion bias. Finally, XAP injection dosage and chemother-
apy are not the same in each study, which could lead to
low heterogeneity for QOLIR and NV.
In conclusion, the positive findings from this study sug-
gest that compared with chemotherapy alone, XAP in-
jection combined with chemotherapy may have benefi-
cial effects in the treatment of advanced NSCLC.
These effects include enhancing ER and QOLIR, and
weakening chemotherapy toxicities. Based on our re-
sults, XAP injection could be considered as a potential
adjuvant therapy in patients with NSCLC. However,
the evidence may be limited by potential bias, so larger
scale RCTs are needed to demonstrate the findings and
understand the long-term effects of Tongguanteng (Ra-
dix seu Herba Marsdeniae Tenacissimae) extract.
REFERENCES
1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman
D. Global cancer statistics. CA Cancer J Clin 2011; 61(2):
69-90.
2 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA.
Non-small cell lung cancer: epidemiology, risk factors,
treatment, and survivorship. Mayo Clin Proc 2008; 83(5):
584-594.
3 Rivera MP. Multimodality therapy in the treatment of
lung cancer. Semin Respir Crit Care Med 2004; 25 Suppl
1: 3-10.
4 Cheng JH, Liu WS, Li ZM, Wang ZG. A clinical study
on global TCM therapy in treating senile advanced
non-small cell lung cancer. Chin J Integr Med 2007; 13
(4): 269-274.
5 Xu L, Li H, Xu Z, et al. Multi-center randomized dou-
ble-blind controlled clinical study of chemotherapy com-
bined with or without traditional Chinese medicine on
quality of life of postoperative non-small cell lung cancer
patients. BMC Complement Altern Med 2012; 12: 112.
6 Zhou WB, He FJ, Jiang WZ, Fu J. Clinical obseration of
Xiaoaiping combined with concurrent chemoradiotherapy
in advanced nasopharyngeal cancer. Lin Chuang Zhong
Liu Xue Za Zhi 2009; 14(11): 1029-1031.
7 Wang Y, Wang RP, Chen JJ. Clinical observation on
Xiaoaiping injection combined with FUDR and DDP reg-
imen in treating advanced primary hepatic carcinoma. Fu-
jian Zhong Yi Yao 2009; 40(3): 14-15.
8 Liu HW, Yu SH, Liu FL, et al. Clinical research of com-
bined Xiaoaiping with chemotherapy treatment of ad-
vanced carcinoma of esophagus. Dang Dai Yi Xue 2013;
19(24): 3-4, 23.
9 Liu XB, Su QS, Mao XP, et al. Effect of Xiaoaiping injec-
tion in the treatment of the elderly patients with advanced
gastric carcinoma. Zhong Liu Ji Chu Yu Lin Chuang
2012; 25(6): 513-514.
10 Zhang MZ, He Z, Wu GY, Xing Z, Song M, Wang RL.
Effect of Xiaoaiping injection on Ec-9706 cell line. Shi
Zhen Guo Yi Guo Yao 2008; 19(5): 1182-1184.
11 Cheng GL, Kong LY, Zhang C. Progress in chemical and
pharmacological studies on Marsdenia tenacissima. Yao
Xue Yu Lin Chuang Yan Jiu 2009; 17(2): 135-138.
12 Deng J, Liao Z, Chen D. Marsdenosides A-H, polyoxy-
pregnane glycosides from Marsdenia tenacissima. Phyto-
chemistry 2005; 66(9): 1040-1051.
13 Zhang H, Tan AM, Zhang AY, Chen R, Yang SB, Huang
X. Five new C21 steroidal glycosides from the stems of
Marsdenia tenacissima. Steroids 2010; 75(2): 176-183.
14 Ye B, Yang J, Li J, Niu T, Wang S. In vitro and in vivo an-
titumor activities of tenacissoside C from Marsdenia tena-
cissima. Planta Med 2014; 80(1): 29-38.
15 Qian J, Hua HQ, Qin SK. Progress on antitumor effects
of Marsdenia tenacissima. Zhong Guo Zhong Yao Za Zhi
2009; 34(1): 11-13.
16 Buccheri G, Ferrigno D, Tamburini M. Karnofsky and
268
Zhang HM et al. / Systematic Review
JTCM |www. journaltcm. com June 15, 2016 |Volume 36 | Issue 3 |
ECOG performance status scoring in lung cancer: a pro-
spective, longitudinal study of 536 patients from a single
institution. Eur J Cancer 1996; 32A(7): 1135-1141.
17 Shuster A, Huynh TJ, Rajan DK, et al. Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria are superi-
or to European Association for Study of the Liver (EASL)
criteria at 1 month follow-up for predicting long-term sur-
vival in patients treated with transarterial chemoemboliza-
tion before liver transplantation for hepatocellular cancer.
J Vasc Interv Radiol 2013; 24(6): 805-812.
18 Miller AB, Hoogstraten B, Staquet M, Winkler A. Report-
ing results of cancer treatment. Cancer 1981; 47(1):
207-214.
19 Review Manager (RevMan) (Computer program). Version
5.2 Copenhagen: The Nordic Cochrane Centre, The Co-
chrane Collaboration, 2012.
20 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Mea-
suring inconsistency in Meta-analyses. BMJ 2003; 327
(7414): 557-560.
21 Song CP. Xiaoaiping injection combining with chemo-
therapy in the treatment of 36 patients with advanced
non-small cell lung cancer. Zhong Yi Za Zhi 2008; 49(6):
494.
22 Luan TW, Zhuang H, Lu KP. Clinical research of com-
bined Xiaoaiping with platinum-based in treatment of
non-small cell lung cancer. Zhong Guo Zhong Yi Yao Ke
Ji 2013; 20(5): 533-535.
23 Wang K, Guo ZX. Xiaoaiping injection combining with
NP regiment in the treatment of 56 patients with ad-
vanced lung cancer. Zhong Liu Ji Chu Yu Lin Chuang
2009; 22(1): 47-48.
24 Wang WY, Zhou Y, Zhang XJ, Gao TH, Luo ZF, Liu MY.
A random study of Xiaoaiping injection combined with
chemotherapy on the treatment of advanced non-small
cell lung cancer. Lin Chuang Zhong Liu Xue Za Zhi
2009; 14(10): 936-938.
25 Xia GA. Effect of Xiaoaiping injection combined with TP
regimen in the treatment of advanced non-small cell lung
cancer. Lin Chuang Yi Yao Shi Jian 2013; 22(2): 83-85.
26 Yang H, Lǚ S, Wang Y, Zhang CY. Effect of Xiaoaiping in-
jection combined with NP regimen in the treatment of ad-
vanced NSCLC. Zhong Guo Yi Yao Dao Bao 2011; 8(8):
64-65.
27 Zhang FY, Li QW, Guan JZ, Cui LP. Curative observa-
tion of Xiaoaiping injection combined with GP regimen
in the treatment of patients with advanced non-small cell
lung cancer. Zhong Liu Ji Chu Yu Lin Chuang 2011; 24
(5): 415-417.
28 Zhang RX, Yue JT, Wang TP, Pang L. Clinical research of
combined Xiaoaiping with chemotherapy in treatment of
advanced non-small cell lung cancer. Zhong Liu Ji Chu Yu
Lin Chuang 2012; 25(05): 438-440.
29 Wang SB, Liu WW, Qi XH, Liu J, Guo Q. Clinical re-
search of docetaxel combined with Xiaoaiping injection
treatment of advanced non-small cell lung cancer. Xian
Dai Zhong Xi Yi Jie He Za Zhi 2013; 22(30): 3334-3336.
30 Wang YT. Clinical study on Xiaoaiping injection com-
bined with GP regimen in the treatment of patients with
advanced non-small cell lung cancer. Qingdao Yi Yao Wei
Sheng 2012; 44(4): 246-248.
31 Liu Z, Xu Z, Xu LS. Clinical research of combined
Xiaoaiping injection with chemotherapy treatment of ad-
vanced non-small cell lung cancer. Xian Dai Zhong Xi Yi
Jie He Za Zhi 2008; 17(30): 4720-4721.
32 Zhang ZH, Zhang HD. Pemetrexeddisodium combining
with Xiaoaiping injection in the treatment of 32 patients
with advanced non-small cell lung cancer. Zhong Guo Yi
Yao Zhi Nan 2012; 10(12): 553-554.
33 Zhang XH. Effect of combined Xiaoaiping with NP regi-
ment in the treatment of advanced non-small cell lung can-
cer. She Qu Yi Xue Za Zhi 2009; 7(13): 81.
34 Huang ZQ, Tan H, Wang CY, et al. Clinical research of
combined Xiaoaiping injection with chemotherapy on ad-
vanced non-small cell lung cancer. Lin Chuang Zhong Liu
Xue Za Zhi 2007; 12(2): 97-99, 102.
35 Li J, Zhang H. Clinical research of combined gemcitabine
with Xiaoaiping injection on advanced non-small cell lung
cancer:lower toxicity and higher efficacy. Shi Yong Zhong
Liu Za Zhi 2009; 23(4): 307-310, 374.
36 Petrisor BA, Keating J, Schemitsch E. Grading the evi-
dence: levels of evidence and grades of recommendation.
Injury 2006; 37(4): 321-327.
37 Wang Q, He XR, Tian JH, et al. A Meta-analysis of Aidi
injection plus taxotere and cisplatin in the treatment of
non-small cell lung cancer. Zhong Guo Fei Ai Za Zhi
2010; 13(11): 1027-1034.
38 Yan XL, Gu YH. Meta-analysis of Kanglaite injection
combined with NP regimen chemotherapy for advanced
non-small cell lung cancer. Zhong Guo Quan Ke Yi Xue
2013; 16(4): 431-435.
39 Zhang WL, Yan TH, Liu B, et al. Systematic reviews and
Meta-analysis of Shenmai injection with chemotherapy on
treament of patients with NSCLC. Shi Yong Yao Wu Yu
Lin Chuang 2011; 14(2): 95-101.
40 Zhang L, Chen FY, Xu SF, Ye YP, Li XY. Steroidal agly-
cones from stems of Marsdenia tenacissima that inhibited
the hedgehog signaling pathway. Nat Prod Commun
2014; 9(2): 155-156.
41 Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J,
Kourea H, Papadaki H. Overexpression of hedgehog path-
way molecules and FOXM1 in non-small cell lung carcino-
mas. Lung Cancer 2009; 66(1): 64-74.
42 Chen TS, Wang XP, Wang ZP, Wang LX, Wang HY, Xing
D. Fluorescence emission analysis of caspase-3 activation
induced by Xiaoaiping (XAP) inside living human lung ad-
enocarcinoma cells. Guang Pu Xue Yu Guang Pu Fen Xi
2008; 28(6): 1327-1331.
43 Ye B, Li J, Li Z, Yang J, Niu T, Wang S. Anti-tumor activi-
ty and relative mechanism of ethanolic extract of Marsde-
nia tenacissima (Asclepiadaceae) against human hematolog-
ic neoplasm in vitro and in vivo. J Ethnopharmacol 2014;
153(1): 258-267.
44 Han SY, Zhao MB, Zhuang GB, Li PP. Marsdenia tenacis-
sima extract restored gefitinib sensitivity in resistant non-
small cell lung cancer cells. Lung Cancer 2012; 75(1):
30-37.
45 Han SY, Zhao HY, Zhou N, Zhou F, Li PP. Marsdenia te-
nacissima extract inhibits gefitinib Metabolism in vitro by
interfering with human hepatic CYP3A4 and CYP2D6 en-
zymes. J Ethnopharmacol 2014; 151(1): 210-217.
269
JTCM |www. journaltcm. com June 15, 2016 |Volume 36 | Issue 3 |
Zhang HM et al. / Systematic Review
46 Huang T, Gong WH, Zou CP, et al. Marsdenia tenacissi-
ma extract sensitizes MG63 cells to doxorubicin-induced
apoptosis. Genet Mol Res 2014; 13(1): 354-362.
47 Hu YJ, Shen XL, Lu HL, et al. Tenacigenin B derivatives
reverse P-glycoprotein-mediated multidrug resistance in-
HepG2/Dox cells. J Nat Prod 2008; 71(6): 1049-1051.
48 Huang Z, Lin H, Wang Y, Cao Z, Lin W, Chen Q. Stud-
ies on the anti-angiogenic effect of Marsdenia tenacissima
extract in vitro and in vivo.Oncol Lett 2013; 5(3): 917-922.
49 Zhu X, Li Y, Yue Y, Li X, Hao X. Study on extraction and
immune regulation of polysaccharides from Marsdenia te-
nacissima. Zhong Guo Zhong Yao Za Zhi 2012; 37(4):
457-460.
50 Chan K, Shaw D, Simmonds MS, et al. Good practice in
reviewing and publishing studies on herbal medicine, with
special emphasis on traditional Chinese medicine and Chi-
nese materia medica. J Ethnopharmacol 2012; 140(3):
469-475.
51 Uzuner H, Bauer R, Fan TP, et al. Traditional Chinese
medicine research in the post-genomic era: good practice,
priorities, challenges and opportunities. J Ethnopharmacol
2012; 140(3): 458-468.
270
